These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 23429710)
41. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female. Bonny AE; Harkness LS; Cromer BA Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540 [TBL] [Abstract][Full Text] [Related]
42. Effect of injectable contraceptive use on response to antiretroviral therapy among women in Rakai, Uganda. Polis CB; Nakigozi G; Ssempijja V; Makumbi FE; Boaz I; Reynolds SJ; Ndyanabo A; Lutalo T; Wawer MJ; Gray RH Contraception; 2012 Dec; 86(6):725-30. PubMed ID: 22717186 [TBL] [Abstract][Full Text] [Related]
43. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins LT; Hanson D; Heneine W; García-Lerma JG AIDS; 2014 Jun; 28(10):1431-9. PubMed ID: 24759208 [TBL] [Abstract][Full Text] [Related]
44. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Canto de Cetina TE; Luna MO; Cetina Canto JA; Bassol S Contraception; 2004 Feb; 69(2):115-9. PubMed ID: 14759615 [TBL] [Abstract][Full Text] [Related]
46. Progestin-only contraception: injectables and implants. Jacobstein R; Polis CB Best Pract Res Clin Obstet Gynaecol; 2014 Aug; 28(6):795-806. PubMed ID: 24996766 [TBL] [Abstract][Full Text] [Related]
47. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo. Abasiattai AM; Udoma EJ; Ukeme E Ann Afr Med; 2010; 9(2):81-5. PubMed ID: 20587929 [TBL] [Abstract][Full Text] [Related]
48. Time to focus on improving the contraceptive method mix in high HIV prevalence settings and let go of unanswerable questions. Jones HE Contraception; 2014 Oct; 90(4):357-9. PubMed ID: 24993486 [No Abstract] [Full Text] [Related]
49. Monthly injection provides new contraceptive choice. FDA Consum; 2001; 35(1):5. PubMed ID: 11930928 [No Abstract] [Full Text] [Related]
50. Two recent studies find Depo-Provera use increases HIV risk. Harper KN AIDS; 2015 Jun; 29(9):N1. PubMed ID: 25870992 [No Abstract] [Full Text] [Related]
51. Critical Review: Mechanisms of HIV Transmission in Depo-Provera Users: The Likely Role of Hypoestrogenism. Hickey M; Marino JL; Tachedjian G J Acquir Immune Defic Syndr; 2016 Jan; 71(1):1-7. PubMed ID: 26761267 [TBL] [Abstract][Full Text] [Related]
52. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210 [TBL] [Abstract][Full Text] [Related]
54. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa. Beksinska ME; Rees HV Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932 [TBL] [Abstract][Full Text] [Related]
55. Depomedroxyprogesterone acetate use and weight gain among adolescents. Templeman C; Boyd H; Hertweck SP J Pediatr Adolesc Gynecol; 2000 Feb; 13(1):45-6. PubMed ID: 10841626 [No Abstract] [Full Text] [Related]
58. End of the debate on hormonal contraception and HIV risk? Lancet Infect Dis; 2015 Feb; 15(2):131. PubMed ID: 25749056 [No Abstract] [Full Text] [Related]
59. Chlamydia, gonorrhoea, and injectable progesterone. Dayan L; Donovan B Lancet; 2004 Oct 16-22; 364(9443):1387-8. PubMed ID: 15488203 [No Abstract] [Full Text] [Related]